Moderna reorganizes to sharpen focus on vaccine sales, chief commercial officer to leave companyMarket Watch • 12/12/23
Moderna Announces Changes to Commercial Organization to Prepare for Multiple Product Launches in 2024 and 2025Accesswire • 12/12/23
Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor EventAccesswire • 12/07/23
Moderna, Inc. (MRNA) Presents at 35th Annual Piper Sandler Healthcare Conference (Transcript)Seeking Alpha • 11/30/23
Covid vaccine rates in the U.S. are slumping — and it will be a challenge to boost themCNBC • 11/30/23
Moderna Stock Looks Sick; Here's How To Take Advantage With OptionsInvestors Business Daily • 11/30/23
Moderna stock falls as mRNA patent called ‘invalid' by European Patent OfficeProactive Investors • 11/21/23
Moderna Nears Key Technical Level With Indications Of Reversal (Rating Upgrade)Seeking Alpha • 11/20/23
Is Moderna Stock A Sell After Its Sales Guidance Undercuts 2024 Expectations?Investors Business Daily • 11/15/23
Moderna to Host Second Environmental, Social and Governance (ESG) Investor Event on December 7th, 2023Accesswire • 11/14/23